Raymond Hohl

Raymond Hohl, MD, PhD is the Director of the Penn State Cancer Institute and holds the Rice Family Foundation Professorship in the Penn State Cancer Institute within the Department of Medicine at Penn State College of Medicine. He serves as a Professor in the Department of Molecular and Precision Medicine and is a member of multiple research centers including the Division of Hematology and Oncology, the Advisory Committee of the Neuroscience Institute, the One Health Microbiome Center, and the Cancer Institute's Next-Generation Therapies program.

• Penn State Cancer Institute - Director
• Department of Medicine - Rice Family Foundation Professor
• Department of Molecular and Precision Medicine - Professor
• Division of Hematology and Oncology - Member
• Neuroscience Institute - Advisory Committee Member
• One Health Microbiome Center - Member

Dr. Hohl is an internationally recognized expert in isoprenoid metabolism with extensive experience as a clinical and translational researcher. His primary research interests focus on human brain tumors, the isoprenoid pathway as it applies to human health and disease (specifically related to cancers), and prostate cancers. His work has significant implications for the UN Sustainable Development Goals, particularly those related to good health and well-being.

Analysis of Dr. Hohl's recent publications reveals a strong focus on hematological malignancies and stem cell transplantation. His research spans multiple myeloma treatment optimization, GVHD prophylaxis strategies, infection prevention in transplant patients, and genetic factors affecting transplant outcomes. The work demonstrates a consistent translational approach connecting basic science discoveries to clinical applications.

• Carver Clinician, Scientist Award (1991)
• Clinical Pharmacology Faculty Development Award, Pharma Foundation (1992)
• Laureate Award, American College of Physicians (2001)
• Outstanding Research Award in Clinical Pharmacology, Central Society for Clinical Research (1995)
• Outstanding Research Award, GCRC Program Directors' Association (1996)
• Paul E. Carson, Pharmacology Award (1988)
• Young Investigator Award, American Society of Clinical Oncology (1992)

Dr. Hohl has secured substantial research funding throughout his career, including the Cancer Center Support Grant (2000-2026) as Co-PI, Targeting the chondrosarcoma extracellular matrix for drug delivery (2014-2016) as PI, and multiple Career Development Programs funded by the National Cancer Institute. His research fingerprint reveals expertise in geranylgeranyl pyrophosphate, isoprenoids, bisphosphonates, and lovastatin pathways as they relate to malignant neoplasms. He leads the Cancer Institute's Next-Generation Therapies program and collaborates extensively with the One Health Microbiome Center and Neuroscience Institute.